4.7 Article

Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial

Journal

LANCET NEUROLOGY
Volume 11, Issue 2, Pages 140-149

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(11)70308-8

Keywords

-

Funding

  1. National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS), National Parkinson Foundation, Parkinson Alliance
  2. Medtronic Inc
  3. Pfizer Pharma
  4. GlaxoSmithKline
  5. St Jude Medical Neuromodulation Division
  6. Allergan
  7. Allon Therapeutics
  8. Ceregene Inc
  9. Chelsea Therapeutics
  10. Diana Helis Henry Medical Research Foundation
  11. EMD Serono
  12. Huntington's Disease Society of America
  13. Huntington Study Group
  14. Impax Pharmaceuticals
  15. Ipsen Limited
  16. Lundbeck Inc
  17. Michael J Fox Foundation for Parkinson Research
  18. Medtronic
  19. Merz Pharmaceuticals
  20. NIH
  21. National Parkinson Foundation
  22. Neurogen
  23. Teva Pharmaceutical Industries Ltd
  24. University of Rochester
  25. Parkinson Study Group
  26. Veterans Administration
  27. Toyama Pharmaceuticals
  28. NINDS
  29. Fox Foundation
  30. TEVA pharmaceuticals
  31. Medivation Inc
  32. CHDI
  33. Batten Disease Support and Research Association
  34. FDA
  35. Boston Scientific
  36. St Jude Medical Neuromodulation Division (Neuropsychological Testing recommendations and Data Safety Monitoring Board)

Ask authors/readers for more resources

Background The effects of constant-current deep brain stimulation (DBS) have not been studied in controlled trials in patients with Parkinson's disease. We aimed to assess the safety and efficacy of bilateral constant-current DBS of the subthalamic nucleus. Methods This prospective, randomised, multicentre controlled trial was done between Sept 26, 2005, and Aug 13, 2010, at 15 clinical sites specialising in movement disorders in the USA. Patients were eligible if they were aged 18-80 years, had Parkinson's disease for 5 years or more, and had either 6 h or more daily off time reported in a patient diary of moderate to severe dyskinesia during waking hours. The patients received bilateral implantation in the subthalamic nucleus of a constant-current DBS device. After implantation, computer-generated randomisation was done with a block size of four, and patients were randomly assigned to the stimulation or control group (stimulation:control ratio 3:1). The control group received implantation without activation for 3 months. No blinding occurred during this study, and both patients and investigators were aware of the treatment group. The primary outcome variable was the change in on time without bothersome dyskinesia (ie, good quality on time) at 3 months as recorded in patients' diaries. Patients were followed up for 1 year. This trial is registered with ClinicalTrials.gov, number NCT00552474. Findings Of 168 patients assessed for eligibility, 136 had implantation of the constant-current device and were randomly assigned to receive immediate (101 patients) or delayed (35 patients) stimulation. Both study groups reported a mean increase of good quality on time after 3 months, and the increase was greater in the stimulation group (4.27 h vs 1.77 h, difference 2.51 [95% CI 0.87-4.16]; p=0.003). Unified Parkinson's disease rating scale motor scores in the off-medication, on-stimulation condition improved by 39% from baseline (24.8 vs 40.8). Some serious adverse events occurred after DBS implantation, induding infections in five (4%) of 136 patients and intracranial haemorrhage in four (3%) patients. Stimulation of the subthalamic nucleus was associated with dysarthria, fatigue, paraesthesias, and oedema, whereas gait problems, disequilibrium, dyskinesia, and falls were reported in both groups. Interpretation Constant-current DBS of the subthalamic nucleus produced significant improvements in good quality on time when compared with a control group without stimulation. Future trials should compare the effects of constant-current DBS with those of voltage-controlled stimulation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available